VEGF-Grab

VEGF-Grab is a recombinant decoy receptor fusion protein designed to inhibit angiogenesis and inflammation by simultaneously targeting Vascular Endothelial Growth Factor (VEGF) and Placental Growth Factor (PlGF). It consists of the second and third immunoglobulin-like domains of VEGFR1 fused to an Fc fragment. The molecule features engineered glycosylation sites to minimize non-specific binding to the extracellular matrix (ECM), thereby improving its pharmacokinetic profile. Originally developed for oncology, it is being investigated for autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and multiple sclerosis, where it suppresses pathological vessel formation, inhibits the invasive behavior of fibroblast-like synoviocytes, and modulates pathogenic Th17 cell activity. The improved version, PB102, demonstrates enhanced molecular stability and binding affinity compared to the original PB101 candidate.

Other names

VEGF decoy receptor fusion protein